X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (14726) 14726
Publication (757) 757
Newsletter (140) 140
Book Review (88) 88
Magazine Article (21) 21
Book Chapter (10) 10
Conference Proceeding (9) 9
Dissertation (5) 5
Newspaper Article (5) 5
Book / eBook (1) 1
Data Set (1) 1
Government Document (1) 1
Paper (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (13535) 13535
female (10145) 10145
middle aged (9389) 9389
male (8467) 8467
aged (8336) 8336
fluorouracil - administration & dosage (7872) 7872
oncology (7534) 7534
adult (7072) 7072
antineoplastic combined chemotherapy protocols - therapeutic use (6590) 6590
fluorouracil - adverse effects (6307) 6307
antineoplastic combined chemotherapy protocols - adverse effects (5974) 5974
chemotherapy (5138) 5138
fluorouracil (5005) 5005
index medicus (4939) 4939
treatment outcome (3616) 3616
cancer (3549) 3549
fluorouracil - therapeutic use (2959) 2959
5-fluorouracil (2947) 2947
colorectal neoplasms - drug therapy (2554) 2554
drug administration schedule (2263) 2263
leucovorin - administration & dosage (2232) 2232
capecitabine (2212) 2212
deoxycytidine - analogs & derivatives (2176) 2176
antineoplastic combined chemotherapy protocols - administration & dosage (2137) 2137
cisplatin - administration & dosage (2094) 2094
aged, 80 and over (2058) 2058
breast neoplasms - drug therapy (2024) 2024
colorectal cancer (1966) 1966
leucovorin (1948) 1948
fluorouracil - analogs & derivatives (1915) 1915
disease-free survival (1861) 1861
adenocarcinoma - drug therapy (1748) 1748
oxaliplatin (1740) 1740
neoplasm staging (1665) 1665
therapy (1653) 1653
combined modality therapy (1620) 1620
cisplatin (1551) 1551
organoplatinum compounds - administration & dosage (1543) 1543
colorectal neoplasms - pathology (1542) 1542
antimetabolites, antineoplastic - adverse effects (1541) 1541
care and treatment (1535) 1535
deoxycytidine - administration & dosage (1526) 1526
carcinoma (1494) 1494
survival rate (1473) 1473
pharmacology & pharmacy (1463) 1463
neoplasm metastasis (1418) 1418
antineoplastic agents - adverse effects (1415) 1415
survival analysis (1389) 1389
trial (1376) 1376
retrospective studies (1347) 1347
chemotherapy, adjuvant (1322) 1322
camptothecin - analogs & derivatives (1318) 1318
research (1301) 1301
leucovorin - adverse effects (1298) 1298
deoxycytidine - adverse effects (1286) 1286
surgery (1234) 1234
radiotherapy (1224) 1224
stomach neoplasms - drug therapy (1181) 1181
organoplatinum compounds - adverse effects (1177) 1177
survival (1173) 1173
medicine & public health (1139) 1139
irinotecan (1117) 1117
infusions, intravenous (1114) 1114
metastasis (1110) 1110
follow-up studies (1105) 1105
antimetabolites, antineoplastic - administration & dosage (1093) 1093
prospective studies (1081) 1081
prognosis (1074) 1074
cyclophosphamide - administration & dosage (1065) 1065
cisplatin - adverse effects (1057) 1057
dose-response relationship, drug (1020) 1020
antineoplastic agents - therapeutic use (1004) 1004
camptothecin - administration & dosage (996) 996
toxicity (988) 988
bevacizumab (974) 974
antimetabolites, antineoplastic - therapeutic use (963) 963
time factors (942) 942
animals (925) 925
carcinoma, squamous cell - drug therapy (917) 917
liver neoplasms - secondary (905) 905
liver neoplasms - drug therapy (904) 904
combination (898) 898
drug therapy (898) 898
colonic neoplasms - drug therapy (874) 874
breast cancer (863) 863
antineoplastic agents - administration & dosage (856) 856
1st-line treatment (847) 847
randomized-trial (810) 810
methotrexate - administration & dosage (809) 809
breast neoplasms - pathology (801) 801
clinical trials (767) 767
drug therapy, combination (758) 758
risk factors (741) 741
health aspects (739) 739
doxorubicin - administration & dosage (735) 735
phase-ii (731) 731
cyclophosphamide - adverse effects (723) 723
docetaxel (699) 699
camptothecin - adverse effects (696) 696
disease progression (689) 689
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (13330) 13330
Japanese (629) 629
French (234) 234
German (227) 227
Chinese (173) 173
Russian (82) 82
Spanish (69) 69
Italian (51) 51
Polish (19) 19
Portuguese (13) 13
Hungarian (12) 12
Danish (11) 11
Dutch (11) 11
Hebrew (7) 7
Korean (7) 7
Norwegian (6) 6
Czech (5) 5
Swedish (5) 5
Slovak (3) 3
Turkish (3) 3
Bulgarian (2) 2
Finnish (2) 2
Romanian (2) 2
Ukrainian (2) 2
Lithuanian (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, ISSN 0446-6586, 2018, Volume 115, Issue 3, p. 290
We report the case of a 61-year-old man who experienced severe adverse effects of capecitabine because of dihydropyrimidine dehydrogenase (DPD) deficiency. In... 
Antimetabolites, Antineoplastic - therapeutic use | Dihydropyrimidine Dehydrogenase Deficiency - diagnosis | Capecitabine - adverse effects | Humans | Middle Aged | Antimetabolites, Antineoplastic - adverse effects | Male | Capecitabine - therapeutic use | Fluorouracil
Journal Article
Archives of Toxicology, ISSN 0340-5761, 12/2018, Volume 92, Issue 12, pp. 3549 - 3564
Journal Article
JAMA, ISSN 0098-7484, 06/2017, Volume 317, Issue 23, pp. 2392 - 2401
IMPORTANCE: Combining biologic monoclonal antibodies with chemotherapeutic cytotoxic drugs provides clinical benefit to patients with advanced or metastatic... 
MEDICINE, GENERAL & INTERNAL | LEUCOVORIN | FIRE-3 | THERAPY | FOLFIRI PLUS CETUXIMAB | PHASE-II | IRINOTECAN | OXALIPLATIN | FLUOROURACIL | TUMORS | PROGRESSION | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Bevacizumab - therapeutic use | United States | Bevacizumab - adverse effects | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Cetuximab - therapeutic use | Cetuximab - adverse effects | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Adult | Camptothecin - administration & dosage | Female | Angiogenesis Inhibitors - adverse effects | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Kaplan-Meier Estimate | Treatment Outcome | Canada | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Colorectal Neoplasms - secondary | Aged | Genes, ras | Organoplatinum Compounds - adverse effects | Chemotherapy | Usage | Care and treatment | Research | Colorectal cancer | Cancer | Drugs | Medical research | Colorectal carcinoma | Clinical trials | Cytotoxicity | Patients | Survival | K-Ras protein | Bevacizumab | Metastases | Survival analysis | Irinotecan | Randomization | Oxaliplatin | Monoclonal antibodies | Tumors
Journal Article
Annals of Oncology, ISSN 0923-7534, 05/2005, Volume 16, Issue 5, pp. 762 - 766
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2014, Volume 371, Issue 17, pp. 1609 - 1618
In patients with metastatic colon cancer, fluorouracil, oxaliplatin, and irinotecan plus bevacizumab, as compared with fluorouracil and irinotecan plus... 
1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | INFUSIONAL FLUOROURACIL | LEUCOVORIN | MANAGEMENT | PHASE-III | GUIDELINES | IRINOTECAN | OXALIPLATIN | CHEMOTHERAPY | FOLFIRI | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Bevacizumab | Fluorouracil - therapeutic use | Antibodies, Monoclonal, Humanized - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Neoplasm Metastasis - drug therapy | Colorectal Neoplasms - drug therapy | Adult | Female | Leucovorin - therapeutic use | Liver Neoplasms - secondary | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Antibodies, Monoclonal, Humanized - adverse effects | Camptothecin - adverse effects | Camptothecin - therapeutic use | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Colorectal Neoplasms - pathology | Organoplatinum Compounds - therapeutic use | Organoplatinum Compounds - adverse effects | Treatment outcome | Care and treatment | Analysis | Colorectal cancer | Dosage and administration | Leucovorin | Fluorouracil | Colorectal carcinoma | Diarrhea | Metastasis | Survival | Patients | Clinical outcomes | Metastases | Irinotecan | Stomatitis | Chemotherapy | Neurotoxicity | Oxaliplatin | Monoclonal antibodies | Vascular endothelial growth factor | Neutropenia | Index Medicus | Abridged Index Medicus
Journal Article
Clinical Breast Cancer, ISSN 1526-8209, 2011, Volume 11, Issue 6, pp. 349 - 356
Journal Article
Annals of Oncology, ISSN 0923-7534, 03/2004, Volume 15, Issue 3, pp. 460 - 466
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 1, pp. 38 - 47
Summary Background Neoadjuvant chemotherapy for unresectable colorectal liver metastases can downsize tumours for curative resection. We assessed the... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | 1ST-LINE TREATMENT | LEUCOVORIN | PLUS IRINOTECAN | ONCOLOGY | BEVACIZUMAB | OXALIPLATIN | FLUOROURACIL | HEPATIC RESECTION | CANCER | CARCINOMA | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Tomography, Spiral Computed | Liver Neoplasms - chemistry | Hepatectomy | Antibodies, Monoclonal, Humanized | Fluorouracil - therapeutic use | Austria | Leucovorin - adverse effects | Fluorouracil - adverse effects | Time Factors | Antineoplastic Agents - adverse effects | Female | Leucovorin - therapeutic use | Neoadjuvant Therapy | Retrospective Studies | Chemotherapy, Adjuvant | Cetuximab | Liver Neoplasms - secondary | Odds Ratio | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Camptothecin - therapeutic use | Liver Neoplasms - genetics | Risk Assessment | Liver Neoplasms - drug therapy | Linear Models | Liver Neoplasms - surgery | Proto-Oncogene Proteins - genetics | Treatment Outcome | Receptor, Epidermal Growth Factor - analysis | Magnetic Resonance Imaging | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Aged | Mutation | Colorectal Neoplasms - pathology | Organoplatinum Compounds - therapeutic use | Germany | Organoplatinum Compounds - adverse effects | Index Medicus
Journal Article